AnchorDx and DiaCarta Collaborate on Novel Cancer Screening Tests

Guangzhou, China-based AnchorDx has entered into a long-term collaboration with DiaCarta for the development and global commercialization of cancer screening products.

Leveraging each company’s proprietary DNA methylation and mutation detection technologies, the two companies will work together to develop and commercialize molecular diagnostic products for the global market.

AnchorDx’s DNA methylation test has been granted Breakthrough Device Designation by the US FDA. Meanwhile, AnchorDx is currently conducting a registrational and prospective clinical study (NCT05643690) for the UriFind PMA application, in which DiaCarta will also participate as one of the clinical testing laboratories.

“Partnering with AnchorDx allows both companies to combine their technical expertise to develop high precision mutation and methylation assays with the needed high sensitivity and specificity to meet the evolving needs for precision diagnostics,” said Dr. Adam (Aiguo) Zhang, CEO and President of DiaCarta.

“We are committed to bringing the best cancer diagnostic products to the global market. To this end, we are pleased to partner with the world’s leading diagnostics company, DiaCarta, to commercialise our leading cancer screening products and to co-develop future cancer screening diagnostic tests,” said Dr Jian-Bing Fan, founder and CEO of AnchorDx.

en_GBEnglish (UK)